Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 6/20 | 0.45 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5782798 | 0.95 | GLA (0.51) | GLAHSD17B10NAMPTAVPR2ALDH1A1 | |
| SCHEMBL5785761 | 0.95 | GLA (0.49) | GLAHSD17B10NAMPTAVPR2ALDH1A1 | |
| SCHEMBL5784629 | 0.93 | NAMPT (0.46) | GLAHSD17B10NAMPTAVPR2ALDH1A1 | |
| SCHEMBL5785130 | 0.92 | NAMPT (0.45) | GLAHSD17B10NAMPTAVPR2ALDH1A1 | |
| SCHEMBL5783944 | 0.89 | NAMPT (0.50) | GLAHSD17B10NAMPTAVPR2ALDH1A1 | |
| SCHEMBL5785070 | 0.89 | NAMPT (0.43) | GLAHSD17B10NAMPTAVPR2ALDH1A1 | |
| SCHEMBL5783704 | 0.88 | AVPR1A (0.51) | GLAHSD17B10NAMPTAVPR2ALDH1A1 | |
| SCHEMBL5785896 | 0.88 | NAMPT (0.50) | GLAHSD17B10NAMPTAVPR2ALDH1A1 | |
| SCHEMBL5783100 | 0.88 | GLA (0.44) | GLAHSD17B10NAMPTAVPR2ALDH1A1 | |
| SCHEMBL5785351 | 0.86 | NAMPT (0.50) | HSD17B10NAMPTALDH1A1TP53MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109193-B2 | Tricyclic diazepines tocolytic oxytocin receptor antagonists | WYETH (US) | 2006-09-19 | — | — | US | claimed |
| EP-1377586-B1 | TRICYCLIC DIAZEPINES AS TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH CORP (US) | 2006-03-22 | — | — | EP | claimed |
| EP-1377586-A1 | TRICYCLIC DIAZEPINES AS TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | Wyeth (US) | 2004-01-07 | — | — | EP | claimed |
| US-20030008863-A1 | Novel tricyclic diazepines tocolytic oxytocin receptor antagonists | WYETH | 2003-01-09 | — | — | US | claimed |
| WO-2002083678-A1 | TRICYCLIC DIAZEPINES AS TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | claimed |
| US-7109193-B2 | Tricyclic diazepines tocolytic oxytocin receptor antagonists | WYETH (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1377586-B1 | TRICYCLIC DIAZEPINES AS TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH CORP (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20030008863-A1 | Novel tricyclic diazepines tocolytic oxytocin receptor antagonists | WYETH | 2003-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008863-A1 | Novel tricyclic diazepines tocolytic oxytocin receptor antagonists | OXTR, OPRL1, HCRTR2 | GLA 4799/4885HSD17B10 2711/4885NAMPT 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.